Economic analysis of insulin initiation by pharmacists in a Canadian setting

Background: Conducted in Alberta, the RxING study examined the effect of a community pharmacist prescribing intervention on glycemic control in patients with uncontrolled type 2 diabetes mellitus (T2DM) using insulin glargine. The objective of this study was to assess the cost-effectiveness of pharmacists’ prescribing of insulin glargine as an early intervention in uncontrolled patients with T2DM vs usual clinical practice. Methods: The IMS CORE diabetes Markov model was used to project long-term clinical outcomes, costs and cost-effectiveness of interventions. The efficacy of insulin glargine, in terms of hemoglobin A1c reduction and hypoglycemia rates, was obtained from the RxING study. Health utility and cost data were found in Canadian publications. The base-case analyses examined the economic and clinical effects of having pharmacists initiate insulin therapy in patients with uncontrolled T2DM in comparison to a physician initiate it up to 3 years later. Results: Insulin initiation by pharmacists with uncontrolled T2DM patients is cost-effective. Having pharmacists prescribe insulin 1 year earlier than usual clinical practice resulted in an incremental cost savings of $805 (CDN$) and a gain of 0.048 QALYs per patient. Pharmacists prescribing insulin 2 years earlier resulted in an incremental cost savings of $624 (CDN$) per year and a gain of 0.075 quality-adjusted life-years (QALYs). Prescribing 3 years earlier allowed for a minor increase of $26 and a gain of 0.086 QALYs. Conclusion: Earlier initiation of insulin by pharmacists, in uncontrolled T2DM patients, resulted in cost savings and delays in the development of diabetes-related complications, leading to an improved quality of life and increased survival rates.

[1]  R. Tsuyuki,et al.  Pharmacist intervention for glycaemic control in the community (the RxING study) , 2013, BMJ Open.

[2]  V. Woo,et al.  Pharmacologic management of type 2 diabetes. , 2013, Canadian journal of diabetes.

[3]  D. Wright,et al.  Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis , 2011, Journal of medical economics.

[4]  A. Willan,et al.  Clinical inertia in patients with T2DM requiring insulin in family practice. , 2010, Canadian family physician Medecin de famille canadien.

[5]  C. Cameron,et al.  Cost-effectiveness of insulin analogues for diabetes mellitus , 2009, Canadian Medical Association Journal.

[6]  Carl van Walraven,et al.  Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? , 2005, Diabetes care.

[7]  Volker Foos,et al.  The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.

[8]  J. Caro,et al.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada , 2003, BMC health services research.

[9]  Andreas Laupacis,et al.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  Lawrence A Leiter,et al.  Out-of-pocket Costs of Managing Hyperglycemia and Hypoglycemia in Patients With Type 1 Diabetes and Insulin-treated Type 2 Diabetes , 2007 .